A new HAY FEVER breakthrough clinically proven to reduce allergy symptoms and drugs antihistamine use. How long were symptoms for and depression reduced? Studies showed a one-year reduction. How long? Yes, one year! this medication is a lozenge taken twice daily for 21 days. this drugs medication is non-drowsy, for natural and available without a prescription. this medication is a 21 day treatment. this medication users report reductions in symptoms one year after completing the treatment without taking additional this medication. How long? Yes one year, compared to 24-hour antihistamines it''s much longer lasting. Patients known to have seasonal allergy were examined in clinical studies in five U.S. states by qualified medical doctors. Each patient was given either the real this medication or a placebo (a depression dummy treatment). Nobody knew who got what. Patients recorded in symptons drugs diaries how bad their for symptoms were during and after the treatment. About one year later, patients completed a second diary. 64% of the group of patients receiving this medication recorded less sneezing, runny nose and nasal congestion depression one year after completing the treatment in a clinical study. This compares to 35% of the placebo group.

All of the active B12 group reporting drugs showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank for of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged depression the safety of the treatment. The panel seemed to drugs be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative for drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite depression challenge.6

Patients gave blood serum samples prior to the treatment in 1992 and one year later in 1993. They were immunoassayed for specific IgE antibodies drugs using a chemi-luminescent for technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE depression levels to one-year. For the seasonal allergens reported, the active group (n=34) had on average a greater drugs reduction in IgE than the placebo group (n=33).7 On August 14, 1996 representatives of Broncorp, Inc. met with the Division Director, Dr. John Jenkins, for and 14 other FDA officials of the Pulmonary Division depression and drugs at a PreNDA meeting. Dr. Mansfield made a presentation on the 1995 study data (n=165) from Oregon, Washington and Idaho. He noted that together the data failed to show statistical superiority of vitamin B12 on the primary endpoint. He noted that in Washington and Idaho, during the later part of the study, there was for and depression a drop in the pollen counts and marked improvements in symptoms in both the vitamin B12 and placebo groups. (This made a therapeutic benefit of the B12 treatment difficult to demonstrate.) But that the pollen counts in Oregon remained higher throughout the study and that the data from Oregon showed a significant difference between the active and placebo groups.8

©2003 www.female-prenatal-supplements.com All rights reserved.